REHOVOT, Israel, Nov. 7, 2022 -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the Company is launching Collink.3D™ 90, a recombinant human collagen (rhCollagen)-based bioink for use in a variety of 3D bioprinting applications. Collink.3D™ 90 is complementary to the Company's first commercial bioink, Collink.3D™ 50, which was launched late last year, offering increased mechanical properties to address additional printing requirements of soft and hard tissues.

Bioinks are applied to a diverse range of soft and hard tissue engineering applications, with each tissue or organ having specific mechanical requirements for fulfilling physiological needs. Thus, the most suitable bioink is required for a given application to mimic the physical properties of the target tissue or organ, while ensuring high cell survival.

"We are very excited to continue to broaden our rhCollagen-based bioink offerings, providing our biopharma and academic customers the ability to print a variety of applications," said CollPlant CEO, Yehiel Tal. "We believe our bioinks deliver a favorable alternative to existing commercial bioinks owing to their high bio-functionality, rheological properties (e.g., controlled viscosity) and high purity. In addition to our product pipeline, bioinks are an important and strategic platform that supports CollPlant's efforts to pursue licensing and collaboration agreements with business partners, and we will continue to introduce new bioinks and innovate in this area", he added.

Collink.3D™ 90 demonstrates faster human cell migration into gel matrices compared with a commercial hydrogel widely used for 2D and 3D cell culture. Cell migration plays a pivotal role in physiological processes such as tissue repair and regeneration, and these initial results indicate the potential for Collink.3D™ 90 to perform as a superior, animal free, human cell culture substrate.

Collink.3D™ enables the high-resolution, scalable and reproduceable 3D bioprinting of scaffolds that accurately mimic the physical properties of human tissues and organs, with improved biofunctionality, safety and reproducibility. Applications for Collink.3D™ include its use in 3D cell culturing, tissue modeling for drug discovery and development, as well as engineering tissues and implantation of organs in regenerative medicine, representing a potential multi-billion-dollar market opportunity. Biofabricated constructs composed of Collink.3D™ offer superior biological performance, consistency and safety. Collink.3D™ is compatible with major 3D bioprinting technologies and cell types including stem cells, induced pluripotent stem cells, endothelial, and epithelial cells.

More information can be found on https://collplant.com/products/collink-3d-new/